Analysts Offer Insights on Healthcare Companies: Miragen Therapeutics Inc (NASDAQ: MGEN), Mesoblast Ltd (NASDAQ: MESO) and Ampliphi Biosciences (AMEX: APHB)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Miragen Therapeutics Inc (NASDAQ: MGEN), Mesoblast Ltd (NASDAQ: MESO) and Ampliphi Biosciences (AMEX: APHB) with bullish sentiments.

Miragen Therapeutics Inc (NASDAQ: MGEN)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Miragen Therapeutics Inc (NASDAQ: MGEN), with a price target of $19. The company’s shares opened today at $7.49.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.2% and a 45.2% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Catabasis Pharmaceuticals.

Currently, the analyst consensus on Miragen Therapeutics Inc is Strong Buy and the average price target is $16.42, representing an 119.2% upside.

In a report issued on June 5, Oppenheimer also assigned a Buy rating to the stock with a $13 price target.

See today’s analyst top recommended stocks >>

Mesoblast Ltd (NASDAQ: MESO)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Mesoblast Ltd (NASDAQ: MESO) today and set a price target of $14. The company’s shares opened today at $6.02.

McCarthy wrote:

“Mesoblast reported (5/30) the March quarter (FY June) with a net loss of $21M and ended the period with $59.5M in cash on the balance sheet. The company has a $75M 4-year credit facility of which $35M was drawn in March. We estimate the company has runway into 4Q18.”

According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 13.8% and a 44.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.

Currently, the analyst consensus on Mesoblast Ltd is Strong Buy and the average price target is $15.20, representing a 152.5% upside.

In a report released today, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $17 price target.

Ampliphi Biosciences (AMEX: APHB)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Ampliphi Biosciences (AMEX: APHB), with a price target of $6. The company’s shares opened today at $1.16.

According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -10.3% and a 34.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.

Ampliphi Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $6.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.